Comparative Efficacy of Rivaroxaban and Immunoglobulin Therapy in the Treatment of Livedoid Vasculopathy: A Systematic Review.

Autor:	Ramphall S; Internal Medicine, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA., Rijal S; Internal Medicine, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA., Prakash V; Internal Medicine, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA., Ekladios H; Psychiatry, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA., Mulayamkuzhiyil Saju J; Internal Medicine, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA., Mandal N; Internal Medicine, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA., Kham NI; Internal Medicine, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA., Shahid R; Internal Medicine, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA., Naik SS; Internal medicine, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA., Venugopal S; Internal Medicine, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA.
Jazyk:	angličtina
Zdroj:	Cureus [Cureus] 2022 Aug 27; Vol. 14 (8), pp. e28485. Date of Electronic Publication: 2022 Aug 27 (Print Publication: 2022).
DOI:	10.7759/cureus.28485
Abstrakt:	Livedoid vasculopathy (LV) is an uncommon chronic coagulation disorder whose underlying etiology is not yet fully understood. It predominantly affects females, especially those in late adolescence. There is currently limited research on treatment options for those with this diagnosis. The present systematic review aims to compare the efficacy of rivaroxaban and intravenous immunoglobulin (IVIG) therapy in the treatment of livedoid vasculopathy. A detailed search was conducted from April 20, 2022, to May 1, 2022, using four databases: Elsevier, Medline Complete, Medline Ovid, and PubMed. Out of these, 20 relevant articles were used, and the data was extracted and analyzed. Both rivaroxaban and IVIG were shown to be effective treatment options with similar treatment response times. However, future large-scale clinical trials are needed to determine an established treatment regimen for these patients. Competing Interests: The authors have declared that no competing interests exist. (Copyright © 2022, Ramphall et al.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu